COMMUNIQUÉS West-GlobeNewswire

AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
16/10/2025
PRESS RELEASE AB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA Paris, 16 October 2025, 9pm CET AB Science SA ( [...]
CJ Biomaterials Introduces New PHACT™ PHA Masterbatch for Safer, Stronger, Softer, Home Compostable Spunbond Nonwovens and Staple Fiber
16/10/2025
Innovative solution that is ideal for wipes, diapers, hygiene, and beauty applications, offering enhanced performance and sustainability WOBURN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- CJ Biomaterials, Inc , a division [...]
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
16/10/2025
Live webcast presentation on Tuesday, October 21st at 11:35 AM ET SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology [...]
Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit
16/10/2025
THE WOODLANDS, TX, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
16/10/2025
Company poster presentations will debut research data of three lead drug candidates constructed with Company’s novel TRBC platform technology MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” [...]
HCW Biologics to Participate in the 2025 Maxim Growth Summit
16/10/2025
MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies [...]
Channel Medsystems Strengthens Commercial Leadership Team with Appointments of Tara Murphy as Vice President of Marketing and Paul Russo as Vice President of Sales
16/10/2025
BERKELEY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Channel Medsystems, Inc., a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointments of Tara Murphy as [...]
VIRBAC annonce son chiffre d'affaires pour le troisième trimestre 2025
16/10/2025
Croissance soutenue du chiffre d’affaires à fin septembre de +7,8% à taux de change et périmètre constants Relèvement des objectifs financiers annuels de chiffre d’affaires Croissance du chiffre d'affaires attendue [...]
VIRBAC Announces Third Quarter 2025 Sales
16/10/2025
Sustained revenue growth at the end of September of +7.8% at constant exchange rates and scope Upgrade of the full-year revenue guidance Revenue growth now expected to be between 5.5% and 7.5% at constant rates and [...]
Press release: NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
16/10/2025
Ghent, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 16 [...]
EssilorLuxottica: Chiffre d'affaires T3/9M 2025 - Chiffre d'affaires en hausse de 11,7 % au T3, meilleure performance trimestrielle du Groupe depuis sa création
16/10/2025
Chiffre d'affaires en hausse de 11,7 % au T3 Meilleure performance trimestrielle du Groupe depuis sa création Chiffre d'affaires T3 du Groupe à +11,7 % à taux de change constants 1 , +8,8 % sur les neuf premiers mois [...]
EssilorLuxottica: Q3/9M 2025 Revenue - Revenue up 11.7% in the third quarter, best quarterly performance ever for the Group
16/10/2025
Revenue up 11.7% in the third quarter Best quarterly performance ever for the Group Group’s revenue +11.7% in the third quarter at constant exchange rates 1 , +8.8% in the nine months Wearables major boost, enlarging [...]
ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
16/10/2025
Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings PRINCETON, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today [...]
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
16/10/2025
Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary endpoint, of 4.3 [...]
Ligand to Host Investor Day on December 9, 2025
16/10/2025
JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:30 a [...]
BPGbio Presents Phase 2 Glioblastoma Data on BPM31510 at ESMO 2025
16/10/2025
BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510 Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to re-potentiate [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/10/2025
WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
16/10/2025
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDT CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE [...]
Cellectis organise aujourd’hui son R&D Day pour présenter les avancées de son portefeuille et ses perspectives à long terme
16/10/2025
L’ensemble des données de phase 1 et la stratégie de l’essai clinique pivot de phase 2 pour le produit candidat lasmé-cel (UCART22) dans la LAL-B en rechute ou réfractaire, seront présentées durant l’événement NEW YORK [...]

Pages